Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News

ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Complete Second Patient Cohort in Clinical Trial for Dry AMD 



November 1, 2012 - (ACT) - "Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company’s three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of two additional patients with dry age-related macular degeneration (dry AMD)."  Read Full Article


Posted on 13-Nov-12 by Gallerno, Jacob
Tags: Science and Industry News
Trackback Url  |  Link to this post | Bookmark this post with: